PBIMA-SOLVx COVID-19 May Be The First Highly Effective Treatment for COVID-19, Patent Pending Treatment Development Methodology Can Create Designs for Future Novel Pathogens In As Little As Two Weeks
DALLAS, October 27, 2020 (Newswire.com) – Dr. John Catanzaro, CEO of Neo7Logix USA LLC, today announced that the company has developed an approach to design highly effective specific-matched Anti-Viral Peptide (AVP) sequences that can be used for the treatment and prevention of novel pathogen diseases. A patent-pending method is used to design a pool of synthetic peptides that act in a multi-mechanistic approach to inhibit virus entry points, prevent viral endocytosis (membrane engulfing), block viral unpacking and replication and stimulate the long-term immune response and eradication of the virus.
This “Precision-Based Immuno-Molecular Augmentation (PBIMA)” design method uses artificial intelligence to guide the design of anti-viral peptides based on the target viral genome sequences and available data on the human population HLA (human leukocyte antigen) susceptibility. Neo7Logix has recently completed a preclinical study that demonstrated greater than 99% reduction of viral load in mice infected with mutant coronavirus HCoV-229E using anti-HCoV-229E (COVID-19) PBIMA-SOLVx with no adverse effects. This proof of concept study also revealed remarkable immunomodulatory stimulation of T and B cells for the immune response. Dr. Catanzaro added, “to our knowledge, there currently is no other highly effective treatment for COVID-19.”
The AVP had no Antibody-Dependent Enhancement (ADE) problem because it induced only CD8+/CD4+ response unlike some current prophylactic vaccines in clinical trials. Existing preclinical data along with computational results show that the AVP designs are non-toxic, non-allergenic and thermostable.
The PBIMA approach can be used to design AVP’s for future novel pathogens in as little as two weeks. Neo7Logix USA LLC is preparing to submit an application to begin clinical trials as soon as possible under the FDA’s Investigational New Drug (IND) program.
Press Contact: Kevin Fowler, CFO Neo7Logix USA LLC, firstname.lastname@example.org
Source: Neo7Logix USA LLC